Arie S. Belldegrun, MD

Arie Belldegrun, MD

Professor and Chief, Department of Urology, Urologic Oncology
Roy and Carol Dumani Chair in Urology
Director, Institute of Urology Oncology





Institutional Affiliation

Ronald Reagan UCLA Medical Center



Surgical Oncology, National Institutes of Health, The Clinical Center, 1985 - 1988
Research, Weizmann Institute of Science, 1976 - 1979


MD, Hebrew University Hadassah Medical School, 1974


Urology, Brigham and Women's Hospital, 1982 - 1985
Surgery, Beilinson Hospital, 1980 - 1982
Urology and Renal Transplantation, Beilinson Hospital, 1979 - 1980

Contact Information


(310) 794-7700 - Information and Referral
(310) 206-1434 - Patients
(310) 794-6584 - Academic
(310) 794-3550 - Nazy Zomorodian, N.P., Director, G.U. Clinical Trials Program

Clinical Interests

BPH Microwave Therapy, Bladder, Bladder Cancer, Cryosurgery, Endoscopic Surgery, Fistula, Gene Therapy, General Urology/ Male, Hematuria, Incontinence, Kidney Cancer, Kidney Cancer Laparoscopy, Kidney General, Laparoscopic Surgery, Masses, Nerve Sparing Prostatectomy, Neurogenic Bladder, Nocturia, Oncology, Penile Cancer, Peyronie's Disease, Prostate Cancer, Prostate General, Prostate Nodules, Reconstructive, Testicular Cancer, Testicular Mass-Pain, Ureteral Obstruction, Urethral Diverticulum, Urethral Obstruction, Urethral/Bladder Stricture, Urinary Diversion, Urinary Obstruction Male

Scientific Interests

Dr. Arie Belldegrun's research focuses on targeted specific therapy and immunotherapy of kidney and prostate cancers.

Belldegrun's laboratory reported on the cloning of a tissue specific and androgen responsive novel 620 bp PSA promoter sequence and upstream sequence. The enhanced gene expression of the resulting construct, combined with its tissue specificity and androgen responsiveness, provide the foundation for the development of tissue specific vectors for prostate cancer gene therapy.

Belldegrun's laboratory also has studied the feasibility of isolating functional dentrictic cells from the peripheral blood of renal cell carcinoma patients and has compared their transduction efficiency using various methods of transferring gene markers into dentritic cells.

Highlighted Publications

Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilguvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2170-5. doi: 10.1073/pnas.1525735113. Epub 2016 Feb 10.

Chamie K, Klopfer P, Bevan P, Storkel S, Said J, Fall B, Belldegrun AS, Pantuck AJ. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial. Urol Oncol. 2015 May;33(5):204.e25-33. doi: 10.1016/j.urolonc.2015.02.013. Epub 2015 Mar 29.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

Birkhauser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. Cancer J. 2013 May-Jun;19(3):189-96. doi: 10.1097/PPO.0b013e318292e8a4.

Birkhauser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM.CAIX in immunocompetent mouse models. J Immunother. 2013 Feb;36(2):102-11. doi: 10.1097/CJI.0b013e31827bec97.